GSK - S-365598 AIMS TO BUILD ON SUCCESS OF DOLUTEGRAVIR AND CABOTEGRAVIR WITH POTENTIAL TO ANCHOR NEXT GENERATION OF LONG-ACTING THERAPIES FOR HIV